Alembic Pharma ropes in Manish Kejriwal as Independent Director
Mumbai: Alembic Pharmaceuticals Limited has appointed Manish Kejriwal as an Independent Director of the company for the period of five consecutive years effective from March 31, 2024. Kejriwal brings over 30 years of experience in private equity investments and is currently the founder and Managing Partner of Kedaara Capital.
Prior to founding Kedaara Capital, Kejriwal served as the head of the India office of Temasek Holdings Pte. Ltd., managing all investments and activities. He also held a prominent role as a Partner at McKinsey & Company, Inc., where he co-founded "The Private Equity Practice" and authored influential reports such as the "NASSCOM McKinsey reports."
Kejriwal holds an AB degree in Engineering Sciences from Dartmouth College and an MBA from Harvard University, where he graduated with high distinction as a Baker Scholar. He currently serves on the boards of Bajaj Finserv Limited, Bajaj Holdings Investment Limited, various Kedaara investee companies, and K Raheja Corp Investment Managers Private Limited.
An active member of the Young Presidents' Organization (YPO) and a Young Global Leader (YGL) recognized by the World Economic Forum, Kejriwal is deeply involved in education initiatives, including the United World College movement and Ashoka University. He has authored articles on private equity in India, featured in leading publications, and is a sought-after speaker at conferences worldwide.
Alembic Pharmaceuticals Limited is a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA.
Read also: Alembic Pharma Slashes the Price of Tofastar by 50% for Benefit of Rheumatoid Arthritis Patients
